• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

    5/29/25 5:00:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email

    INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.

    Lilly will also host an investor event to highlight the company's cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions. The event will be held on Sunday, June 22 at 6:30 p.m. CDT and will be accessible via a live webcast on the "Webcasts & Presentations" section of Lilly's investor website. A replay will be available on the website following the event.

    Presentation Highlights

    Orforglipron (investigational small molecule GLP-1 receptor agonist):

    In an ADA-sponsored symposium, Lilly will share results from the ACHIEVE-1 Phase 3 trial, which evaluated the safety and efficacy of orforglipron in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.

    Insulin efsitora alfa (investigational once-weekly basal insulin):

    In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated once-weekly efsitora in adults with type 2 diabetes.

    Bimagrumab (investigational activin pathway inhibitor):

    In a third ADA-sponsored symposium, Lilly will share results from the BELIEVE Phase 2b trial, which evaluated bimagrumab alone and in combination with semaglutide in adults with overweight or obesity without type 2 diabetes.

    A selection of abstract titles and presentation details are listed below:

    Orforglipron (investigational small molecule GLP-1 receptor agonist):

    Presentation Title: Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?

    Presentation Date & Time: Saturday, June 21, 8 to 9:30 a.m. CDT

    Location: W375 A

    Presenter: Julio Rosenstock, MD

    Insulin efsitora alfa (investigational once-weekly basal insulin):

    Presentation Title: Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!

    Presentation Date & Time: Sunday, June 22, 1:30 to 3 p.m. CDT

    Location: W375 A

    Presenter: Julio Rosenstock, MD; Richard M. Bergenstal, MD; Athena Philis-Tsimikas, MD; Thomas Blevins, MD; Chantal Mathieu, MD, PhD

    Tirzepatide (Zepbound and Mounjaro):

    Presentation Title: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks

    Abstract Number: 103-OR

    Presentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDT

    Location: W185 A-D

    Presenter: Dr. Hiddo L. Heerspink, PhD

    Presentation Title: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)

    Abstract Number: 144-OR

    Presentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDT

    Location: W196 BC

    Presenter: Jamy D. Ard, MD

    Presentation Title: SURMOUNT-5 Tirzepatide vs. Semaglutide for Obesity—Rapid Responders and Associated Weight Reduction and Safety

    Abstract Number: 224-OR

    Presentation Date & Time: Saturday, June 21, 4:30 to 6 p.m. CDT

    Location: W181 A-C

    Presenter: Louis Aronne, MD, FACP, DABOM

    Presentation Title: Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH Trial

    Abstract Number: 226-OR

    Presentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDT

    Location: W181 A-C

    Presenter: Anita Kwan, MSc

    Presentation Title: Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical Trial

    Abstract Number: 227-OR

    Presentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDT

    Location: W181 A-C

    Presenter: Kristina Boye, PhD

    Retatrutide (investigational GIP/GLP-1/glucagon receptor agonist):

    Presentation Title: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity

    Abstract Number: 2169-LB

    Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT

    Location: Poster Hall (Hall F1)

    Presenter: Ansarullah, PhD

    Eloralintide (investigational amylin receptor agonist):

    Presentation Title: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide

    Abstract Number: 849-P

    Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT

    Location: Poster Hall (Hall F1)

    Presenter: Daniel A Briere

    Presentation Title: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept

    Abstract Number: 882-P

    Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT

    Location: Poster Hall (Hall F1)

    Presenter: Edward J. Pratt, MD

    Bimagrumab (investigational activin pathway inhibitor):

    Presentation Title: Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

    Presentation Date & Time: Monday, June 23, 8 to 9:30 a.m. CDT

    Location: W375 A

    Presenters: Lee M. Kaplan, MD, PhD; Ronenn Roubenoff, MD, MHS; Penelope Montgomery, MD; Steven B. Heymsfield, MD; Louis J. Aronne, MD, FACP, DABOM; Ania M. Jastreboff, MD, PhD

    About orforglipron 

    Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published preclinical pharmacology data for this molecule together. Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity.

    About insulin efsitora alfa 

    Insulin efsitora alfa (efsitora) is an investigational once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in Phase 3 development for adults with type 1 and 2 diabetes.

    About retatrutide

    Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and type 2 diabetes, as well as across multiple obesity-related complications, such as osteoarthritis and obstructive sleep apnea.

    About eloralintide

    Eloralintide is an investigational selective, long-acting amylin receptor agonist designed to mimic the effects of native amylin while potentially improving tolerability and quality of weight loss. Lilly is studying eloralintide in clinical trials to evaluate its potential efficacy and safety in obesity.

    About bimagrumab

    Bimagrumab is an investigational monoclonal antibody that blocks activin type II receptors, which may promote muscle growth and fat mass reduction. Bimagrumab was discovered by Novartis and later advanced by Versanis Bio for the treatment of obesity. Versanis Bio was acquired by Lilly in 2023. Lilly is currently running studies of bimagrumab in combination with incretins to assess its ability to improve the quality of weight loss by preserving lean mass while reducing fat mass in adults with overweight or obesity.

    About tirzepatide 

    Tirzepatide is a once-weekly dual GIP receptor and GLP-1 receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and morbidity/mortality in obesity (MMO) are ongoing.

    Tirzepatide has been approved by the U.S. FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control, and as Zepbound for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide is also approved as Mounjaro in some countries outside the U.S. for adults with type 2 diabetes, obesity or those who are overweight who also have a weight-related comorbid condition. Both Mounjaro and Zepbound should be used in combination with diet and exercise.

    INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

    Zepbound (ZEHP-bownd) is an injectable prescription medicine that may help adults with: 

    • obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off. 
    • moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. 

    It should be used with a reduced-calorie diet and increased physical activity. 

    Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. 

    Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider. 

    • Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). 
    • Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 
    • Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. 

    Zepbound may cause serious side effects, including:

    Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away. 

    Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. 

    Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools. 

    Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back. 

    Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat. 

    Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery. 

    Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound. 

    Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you. 

    Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures. 

    Common side effects 

    The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

    Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

    Before using Zepbound 

    • Your healthcare provider should show you how to use Zepbound before you use it for the first time. 
    • Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them. 
    • If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. 

    Review these questions with your healthcare provider: 

    ❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food? 

    ❑ Do you take diabetes medicines, such as insulin or sulfonylureas? 

    ❑ Do you have a history of diabetic retinopathy? 

    ❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)? 

    ❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements? 

    ❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound. 

    • Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). 

    How to take 

    • Read the Instructions for Use that come with Zepbound. 
    • Use Zepbound exactly as your healthcare provider says. 
    • Use Zepbound with a reduced-calorie diet and increased physical activity. 
    • Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. 
    • Use Zepbound 1 time each week, at any time of the day. 
    • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. 
    • If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222. 

    Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial. 

    Learn more

    Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com. 

    This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you. 

    ZP CON BS 20DEC2024

    Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. 

    INDICATION AND SAFETY SUMMARY WITH WARNINGS

    Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).

      • It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.

    Warnings - Mounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

    • Do not use Mounjaro if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
    • Do not use Mounjaro if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
    • Do not use Mounjaro if you are allergic to it or any of the ingredients in Mounjaro.

    Mounjaro may cause serious side effects, including:

    Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.

    Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery.

    Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.

    Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.

    Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

    Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.

    Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools.

    Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Mounjaro may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Mounjaro before you are scheduled to have surgery or other procedures.

    Common side effects

    The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

    Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Before using Mounjaro

    • Your healthcare provider should show you how to use Mounjaro before you use it for the first time.
    • Talk to your healthcare provider about low blood sugar and how to manage it.
    • If you take birth control pills by mouth, talk to your healthcare provider before you use Mounjaro. Birth control pills may not work as well while using Mounjaro. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Mounjaro and for 4 weeks after each increase in your dose of Mounjaro.

    Review these questions with your healthcare provider:

    ❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?❑ Do you take other diabetes medicines, such as insulin or sulfonylureas?

    ❑ Do you have a history of diabetic retinopathy?

    ❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

    ❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? It is not known if Mounjaro will harm your unborn baby or pass into your breast milk.

    ❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

    How to take

    • Read the Instructions for Use that come with Mounjaro.
    • Use Mounjaro exactly as your healthcare provider says.
    • Mounjaro is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
    • Use Mounjaro 1 time each week, at any time of the day.
    • Do not mix insulin and Mounjaro together in the same injection.
    • You may give an injection of Mounjaro and insulin in the same body area (such as your stomach area), but not right next to each other.
    • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
    • If you take too much Mounjaro, call your healthcare provider or seek medical advice promptly.

    Learn more

    Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.

    This summary provides basic information about Mounjaro but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you.

    TR CON CBS 05NOV2024

    Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

    About Lilly

    Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

    Trademarks and Trade Names

    All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements regarding the efficacy, safety and potential regulatory progress of Lilly's investigational medicines such as orforglipron as a potential treatment for adults with type 2 diabetes, insulin efsitora alfa as a potential treatment for adults with type 2 diabetes, retatrutide for potential use across multiple cardiometabolic indications, bimagrumab for potential use alone and in combination with other GLP-1 therapies in adults with overweight or obesity, eloralintide as a potential treatment for obesity and weight management, statements about the efficacy and safety of Zepbound (tirzepatide) as an approved treatment for adults with obesity or overweight, statements about the efficacy and safety of Mounjaro (tirzepatide) as an approved treatment for adults with type 2 diabetes, and reflects Lilly's current belief and expectations. However, as with any investigational and pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that studies will be initiated or completed as planned, that future study results will be consistent with the results to date, that investigational medicines will receive regulatory approval, or that approved medicines will achieve anticipated commercial success. Additionally, regulatory timelines and commercialization efforts may evolve based on emerging data, competitive dynamics, and regulatory interactions. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

    Refer to:

    Brooke Frost; [email protected]; 317-432-9145 (Media)



    Michael Czapar; [email protected]; 317-617-0983 (Investors)

    Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-american-diabetes-associations-ada-85th-scientific-sessions-302468899.html

    SOURCE Eli Lilly and Company

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $LLY
    SEC Filings

    See more
    • SEC Form 11-K filed by Eli Lilly and Company

      11-K - ELI LILLY & Co (0000059478) (Filer)

      6/20/25 4:23:15 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Eli Lilly and Company

      SD - ELI LILLY & Co (0000059478) (Filer)

      5/9/25 4:12:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/8/25 4:34:55 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 31, 2024 - FDA Roundup: May 31, 2024

      For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

      5/31/24 3:22:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 7, 2024 - FDA Roundup: May 7, 2024

      For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

      5/7/24 4:10:24 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 5, 2023 - FDA Roundup: December 5, 2023

      For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

      12/5/23 5:00:21 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sulzberger Gabrielle was granted 6 shares, increasing direct ownership by 0.24% to 2,580 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:28:26 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 18 shares, increasing direct ownership by 0.11% to 16,362 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:26:05 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hedley Mary Lynne was granted 12 shares, increasing direct ownership by 0.63% to 1,960 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:23:14 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eli Lilly downgraded by Erste Group

      Erste Group downgraded Eli Lilly from Buy to Hold

      6/5/25 7:52:21 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously

      4/28/25 8:33:23 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target

      Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00

      4/22/25 7:32:42 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

      Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily

      6/22/25 2:31:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Financials

    Live finance-specific insights

    See more
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

      Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year

      5/1/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

      Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

      11/13/24 9:30:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly appoints Lucas Montarce as executive vice president and chief financial officer

      INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

      9/9/24 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      10/23/24 5:17:34 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      2/13/24 5:04:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      1/26/24 4:25:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care